Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Up 58.0% in April

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 38,400 shares, a growth of 58.0% from the March 31st total of 24,300 shares. Approximately 3.2% of the company’s shares are sold short. Based on an average trading volume of 49,500 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Cyclacel Pharmaceuticals in a research note on Wednesday, April 24th. They set a “hold” rating for the company.

Cyclacel Pharmaceuticals Trading Down 12.7 %

Shares of CYCC stock opened at $1.32 on Monday. Cyclacel Pharmaceuticals has a 12 month low of $1.32 and a 12 month high of $13.20. The company’s fifty day moving average price is $2.26 and its two-hundred day moving average price is $3.79.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($6.23) EPS for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The firm had revenue of $0.03 million during the quarter. On average, analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.